Praluent

Adults w/ primary hypercholesterolaemia (heterozygous familial & non-familial) or mixed dyslipidaemia & in paed patients >8 yr w/ heterozygous familial hypercholesterolaemia (HeFH) as an adjunct to diet in combination w/ a statin or statin w/ other lipid-lowering therapies in patients unable to reach LDL-C goals w/ the max tolerated dose of a statin; or monotherapy or in combination w/ other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated. Prevention of CV events in combination w/ a statin or statin w/ other lipid lowering therapies in patients unable to reach LDL-C goals w/ the max tolerated statin dose; reduce risk of non-fatal MI, ischemic stroke, & unstable angina requiring hospitalization in adults w/ established CV disease.

SC Adult Initially 75 mg once every 2 wk. Alternatively, 300 mg once every 4 wk (mthly). Measure LDL-C w/in 4-8 wk of treatment initiation; if LDL-C response is inadequate, may adjust dose to max of 150 mg every 2 wk. Patient requiring larger LDL-C reduction (>60%) May be started on 150 mg once every 2 wk. Paed patient ≥8 yr w/ HeFH weighing ≥50 kg 300 mg once every 4 wk, or 150 mg once every 2 wk if additional LDL-C reduction is needed, <50 kg 150 mg once every 4 wk, or 75 mg once every 2 wk if additional LDL-C reduction is needed. Assess lipid levels 8 wk after treatment initiation or titration, & adjust dose accordingly.

Hypersensitivity.

Dyslipidaemic Agents

C10AX14 - alirocumab ; Belongs to the class of other lipid modifying agents.

POM